Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$16,880,882
+$4,859,326 QoQ
Shares Held
938,870
+82.9% QoQ
Ownership
1.93%
of shares outstanding
% of Portfolio
0.83%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Derivatives in URGN
reported options exposure · as of Mar 31, 2026CallValue
$899,000
CallShares
50,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026J. Goldman & Co LP holds $186,588,928 across 52 Biotechnology names. URGN ranks #4 (9.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
779,570 | $30,005,649 | |
| 2 | ARDX |
Ardelyx, Inc.
|
3,000,513 | $17,973,072 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
235,260 | $17,665,673 | |
| 4 | URGN |
UroGen Pharma Ltd.
This page
|
938,870 | $16,880,882 | |
| 5 | CAPR |
Capricor Therapeutics, Inc.
|
541,522 | $16,462,268 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,268 | $12,569,307 | |
| 7 | VSTM |
Verastem, Inc.
|
1,680,752 | $8,907,985 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
15,664 | $5,046,784 |
All Filings in URGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $16,880,882 | 938,870 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $899,000 | 50,000 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $1,967,280 | 84,000 | Call | Sole | 2026-02-17 | |
| 2025-12-31 | $12,021,556 | 513,303 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||